SCHEMBL4536199

SCHEMBL4536199

O=C1COC2(CCN(S(=O)(=O)c3ccc(Br)s3)CC2)CN1C1CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FASN P49327 4/20 0.52
TSHR P16473 4/20 0.48
RECQL P46063 1/20 0.48
HTT P42858 2/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 4/20 0.45
LMNA P02545 2/20 0.44
HSD17B10 Q99714 3/20 0.43
MAPK1 P28482 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
EPHX2 P34913 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4537666 0.83 FASN (0.49) FASNTSHRRECQLHTTMAPT
SCHEMBL4536313 0.82 FASN (0.63) FASNTSHRHTTALDH1A1LMNA
SCHEMBL4543317 0.81 FASN (0.52) FASNALDH1A1MAPK1MEN1KMT2A
SCHEMBL4533528 0.79 FASN (0.50) FASNTSHRHTTALDH1A1LMNA
SCHEMBL4534544 0.79 FASN (0.54) FASNALDH1A1MAPK1MEN1KMT2A
SCHEMBL4542521 0.79 FASN (0.52) FASNTSHRHTTLMNAMAPK1
SCHEMBL4536955 0.78 FASN (0.58) FASNTSHRHTTALDH1A1LMNA
SCHEMBL4543093 0.78 FASN (0.52) FASNMAPTALDH1A1HSD17B10POLB
SCHEMBL4534373 0.78 FASN (0.51) FASNALDH1A1LMNAMAPK1MEN1
SCHEMBL4540317 0.78 FASN (0.61) FASNTSHRALDH1A1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2637660-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2013-09-18 EP disclosed
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC 2013-09-12 US disclosed
WO-2012064642-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 FASN 1/4885TSHR 3054/4885RECQL 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.